A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

PharmacoEconomics

Volumn 9, Issue SUPPL. 2, 1996, Pages 8-22

  Hutton, J ^a   Brown, R ^a   Borowitz, M ^a   Abrams, K ^b   Rothman, M ^c   Shakespeare, A ^a  

^a MEDTAP International Inc   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTHRALGIA; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION MAKING; FEMALE; FEVER; HUMAN; INFECTION; META ANALYSIS; METASTASIS; MULTICENTER STUDY; MYALGIA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SKIN TOXICITY;

EID: 0029909833     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199600092-00004     Document Type: Conference Paper

References (45)

1. Drummond M, Futten F, Brenna A, et al. Economic evaluation of pharmaceuticals: a European perspective. Pharmaco-Economics 1993; 4 (3): 173-86
2. Williams C, Coyle D, Uyl-de-Groot C, et al. European School of Oncology Advisory Report to the Commission of the European Communities for the 'Europe Against Cancer Programme' Cost-effectiveness in Cancer Care. Eur J Cancer 1995; 31A: 1410-24
3. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 40: 593
4. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44 Suppl. 4: 17-28
5. Henderson IC. Chemotherapy for metastatic disease. In Harris JR, Hellman S, Henderson IC, et al., editors. Breast diseases. 2nd ed. Philadelphia: JB Lippincott, 1991: 604-5
6. Jones S, Winer E, Vogel C, et al. Randomised comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13: 2567-74
7. Vandenberg TA. New developments in chemotherapy for metastatic breast cancer. Anti-Cancer Drugs 1994; 5: 251-9
8. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere®) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1995: 5 (6): 527-32
9. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22
10. Hudis CA, Seidman AD, Crown JPA, et al. Phase II pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 58-65
11. Trudeau ME, Eisenhauer E, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14: 422-8
12. Ravdin PM, Burris HA III, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85
13. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the treatment of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94
14. Guastalla JP, Bonneterre J, Fumoleau P, et al. A phase II trial of docetaxel in patients (pts) with anthracycline resistant (AR) metastatic breast cancer (MBC) [abstract]. 8th European Conference on Clinical Oncology and Cancer Nursing (ECCO), Paris, 29 Oct-2 Nov, 1995
15. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991; 324 (3): 160-8
16. Hillner BE, Smith TJ. Should women with node-negative breast cancer receive adjuvant chemotherapy? - Insights from a decision analysis model. Breast Cancer Res Treat 1992; 23: 17-27
17. Epstein RJ. Does the breast cancer dollar make sense? Eur J Cancer 1992; 28 (2): 486-91
18. Richards MA, Braysher S, Gregory WM, et al. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993; 67: 856-60
19. de Koning HJ, van Ineveld BM, de Haes JC, et al. Advanced breast cancer and its prevention by screening. Br J Cancer 1992; 65: 950-5
20. Hurley SF, Huggins RM, Snyder RD, et al. The cost of breast cancer recurrences. Br J Cancer 1992; 65: 445-9
21. Desch CE, Hillner BE, Smith TJ. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life expectancy outcomes. J Clin Oncol 1993; 11 (4): 777-82
22. Seidman A. Quality of life in metastatic breast cancer. The impact of taxol. Comparisons between FLIG, rand general wellbeing, hand function. McCorcle and Young, MSAS/GOI. BMS
23. Cochrane WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29
24. Louis TA, Fineburg H, Mosteller F. Findings for public health from meta-analysis. Annual reviews of public health. Palo Alto, CA: Annual Reviews Inc., 1985: 1-20
25. Summary of Product Characteristics for Taxotere® (docetaxel). Rhône-Poulenc Rorer, November 1995
26. Taxolere® Prescribing Information, US Datasheet 1996
27. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81
28. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center Trial. J Clin Oncol 1995; 13: 2056-65
29. Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-9
30. Taxol® Prescribing Information Datasheet, 1996
31. Rothman ML, Hedrick SC, Bulcroft KA, et al. The validity of proxy-generated scores as measures of patient health status. Med Care 1991; 29: 115
32. Furlong W, Feeny D, Torrance GW. Guide to design and development of health state utility instrumentation. Hamilton, Ontario: McMaster University, 1990
33. Froberg DG, Kane RL. Methodology for measuring health-state preferences. III. Population and context effects. J Clin Epidemiol 1989; 42 (c): 585-92
34. NHS Executive 1994. Hospital and Community Health Services Revenue (Pay and Prices) Inflation Index
35. MIMS. Monthly Index of Medical Specialties. London: Haymarket Publishing Services Ltd: May 1996
36. Chartered Institute Public Finance Accountants. Health Database. Health Care Financial Management Association. London: 1992, 1994
37. Drummond M, Davies L. Economic evaluation of lenograstin for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer. PharmacoEconomics 1994; 6 Suppl. 2: 44-52
38. Review body for nursing staff, midwives, health visitors and professions allied to medicine. 11th Report on nursing staff, midwives and health visitors, 1994. CM 2462. HMSO, London: 1994
39. Review body on doctors' and dentists' remuneration. 23rd report, 1994. CM 2460. HMSO, London: 1994
40. West Midlands Regional Health Authority. Extra-contractual referrals tariff. 1992/3
41. Leese B. The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer 1993; 29A Suppl. 7: S15-S18
42. Department of Health and Welsh Office. Drug Tariff. National Health Service, England and Wales. HMSO, London: June 1994
43. Gerard K, Mooney G. QALY league tables. Handle with care. Health Econ 1993; 2: 59-64
44. Laupacis A, Feen D, Detsky A, et al. How attractive does a technology have to be to warrant adoption and utilisation. Can Med Assoc J 1992; 146: 473-81
45. Detsky A. Formulary 1995; 30